USMCA debe ser enmendado para asegurar el acceso a medicamentos en México
Informe Sobre Políticas 64, Agosto de 2019
Maria Fabiana Jorge
Informe Sobre Políticas 64, Agosto de 2019
Maria Fabiana Jorge
The US-Mexico-Canada Agreement: Putting Profits Before Patients
Policy Brief 61, May 2019
Maria Fabiana Jorge
Policy Brief 61, May 2019
Maria Fabiana Jorge
The ‘obvious to try’ method of addressing strategic patenting: How developing countries can utilise patent law to facilitate access to medicines
Policy Brief 59, April 2019
Olga Gurgula
Policy Brief 59, April 2019
Olga Gurgula
Will the Amendment to the TRIPS Agreement Enhance Access to Medicines?
Policy Brief 57, January 2019
Carlos M. Correa
Policy Brief 57, January 2019
Carlos M. Correa
The Use of TRIPS Flexibilities for the Access to Hepatitis C Treatment
Policy Brief 54, October 2018
Germán Velásquez
Policy Brief 54, October 2018
Germán Velásquez
The International Debate on Generic Medicines of Biological Origin
Policy Brief 50, August 2018
Germán Velásquez
Policy Brief 50, August 2018
Germán Velásquez
The Need to Avoid “TRIPS-Plus” Patent Clauses in Trade Agreements
Policy Brief 37, March 2017
Martin Khor
Policy Brief 37, March 2017
Martin Khor
